# JNJ-90301900

Source: https://onco.cc/drugs/jnj-90301900/  
OnCo record `jnj-90301900` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

JNJ-90301900 is an experimental radioenhancer nanoparticle from Johnson & Johnson Enterprise Innovation in phase 3 trials for head and neck squamous cell carcinoma, with its target not yet stated publicly.

## Summary

JNJ-90301900 is a radioenhancer nanoparticle developed by Johnson & Johnson Enterprise Innovation. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. The sponsor states: A suspension of inert, crystalline hafnium oxide nanoparticles designed to generate oxygen free radicals that destroy cancer cells once activated by ionising radiation. ClinicalTrials.gov describes the intervention as: Suspension of inert, crystalline hafnium oxide particles, designed to generate oxygen free radicals to destroy cancer cells after activation by ionizing radiation. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT04892173 (JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC), in head and neck squamous cell carcinoma. The largest, NCT04892173, plans to enrol 500 participants with primary completion expected 2028-06-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Also known as: JNJ-90301900 (NBTXR3); NBTXR3
- Tags: pipeline; ctgov-ingest
- Modality: radioenhancer nanoparticle
- Mechanism: A suspension of inert, crystalline hafnium oxide nanoparticles designed to generate oxygen free radicals that destroy cancer cells once activated by ionising radiation.

## Sources

- ClinicalTrials.gov: trials of JNJ-90301900: https://clinicaltrials.gov/search?intr=JNJ-90301900

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- companies: [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)
- trials: [A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct06667908/), [JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC](https://onco.cc/trials/nct04892173/), [NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer](https://onco.cc/trials/nct07224152/)

---
JSON: https://onco.cc/api/v1/entities/jnj-90301900.json